BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:QLS32015 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of QLS32015\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07185477-3122@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:QLS32015: Phase 1 readout est. (NCT07185477)
DESCRIPTION:QLS32015\, phase 1\, Multiple Myeloma.\nStudy: A Single-arm Sin
 gle-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With
  BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma\nEstimat
 ed primary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/qls32015#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07185477
URL:https://assetmemo.bio/drug/qls32015#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07018050-3122@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:QLS32015: Phase 2 readout est. (NCT07018050)
DESCRIPTION:QLS32015\, phase 2\, Multiple Myeloma.\nStudy: Phase II Study o
 f QLS32015 Combination Therapy in the Treatment of Multiple Myeloma\nEstim
 ated primary completion: November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/qls32015#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07018050
URL:https://assetmemo.bio/drug/qls32015#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138209-3122@assetmemo.bio
DTSTAMP:20261121T004547Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QLS32015: Phase 3 readout est. (NCT07138209)
DESCRIPTION:QLS32015\, phase 3\, Multiple Myeloma.\nStudy: A Study Comparin
 g QLS32015 Monotherapy Versus Pomalidomide\, Dexamethasone (Pd) or Selinex
 or\, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multip
 le Myeloma\nEstimated primary completion: December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/qls32015#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07138209
URL:https://assetmemo.bio/drug/qls32015#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
